1. Austin, E.A., and Huber, B.E., A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of escherichia coli cytosine deaminase. Mol Pharmacol, 1992. 43: p. 380–387.
2. Barba, D., Hardin, J., Sadelain, M., and Gage, F.H., Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci, 1994. 91: p. 4348–4352.
3. Bi, W.L., Parysek, L.M., Warnick, R., and Stambrook, P.J., In vitro evidence that metabolic cooperation is reponsible for the Bystander Effect observed with HSV tk retroviral gene therapy. Human Gene Therapy, 1993. 4: p. 725–731.
4. Bi, W., Kim, Y.G., Feliciano, E.S., Pavelic, L., Wilson, K.M., Pavelic, Z.P., and Stambrook, P.J., An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Therapy, 1997. 4(4): p. 246–252.
5. Boring, C.C., Squires, T.S., and Tong, T., Cancer statistics 1992. Ca. A Cancer Journal for Clinicians, 1992.42: p